群体药物代谢动力学方法研究伏立康唑的变异度:以优化给药方案
发布时间：2019-07-28 13:46
【摘要】：正伏立康唑为广谱抗真菌药物,主要经肝药代谢酶CYP2C19、或CYP3A4和CYP2C9代谢,其药动学特征呈非线性并变异程度大,且该药治疗窗窄,使临床应用复杂。本研究将4项健康受试者研究和2项患者临床研究的数据(包括240名受试者的3 352个血药浓度数据)建立非线性混合效应模型分析(NONMEM),以剂量模拟检验协变量影响效应和据CYP2C19表型分层的伏立康唑浓度(2~5 mg/L)达
[Abstract]:N-voliconazole is a broad-spectrum antifungal drug, which is mainly metabolized by liver drug metabolizing enzymes CYP2C19, or CYP3A4 and CYP2C9. Its pharmacokinetics is nonlinear and varied greatly, and the therapeutic window of the drug is narrow, which makes the clinical application complex. In this study, a nonlinear mixed effect model was established based on the data of 4 healthy subjects and 2 clinical studies (including 3,352 blood concentration data of 240 subjects). (NONMEM), was analyzed by dose simulation to test the covariable effect and the concentration of voliconazole layered according to CYP2C19 phenotype (2 鈮，
本文编号：2520106
[Abstract]:N-voliconazole is a broad-spectrum antifungal drug, which is mainly metabolized by liver drug metabolizing enzymes CYP2C19, or CYP3A4 and CYP2C9. Its pharmacokinetics is nonlinear and varied greatly, and the therapeutic window of the drug is narrow, which makes the clinical application complex. In this study, a nonlinear mixed effect model was established based on the data of 4 healthy subjects and 2 clinical studies (including 3,352 blood concentration data of 240 subjects). (NONMEM), was analyzed by dose simulation to test the covariable effect and the concentration of voliconazole layered according to CYP2C19 phenotype (2 鈮，
本文编号：2520106
本文链接：https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2520106.html
最近更新
教材专著
